Ultravist 370 Infusion
Iopromide
(370 mg)
Zydus Pharmaceuticals
| Pack size | |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 2812.59 NPR |
Indications
Ultravist 370 Infusion is used for:
Adult Dose
Digital Subtraction Angiography
150 mg/mL, intra-arterial single injection dose
Carotid arteries: 6-10 mL
Vertebral arteries: 4-8 mL
Aorta: 20-50 mL
Major branches of the abdominal aorta: 2-20 mL
Not to exceed 250 mL cumulative dose
Cerebral Arteriography
300 mg/mL, intra-arterial single injection dose
Carotid arteries: 3-12 mL
Vertebral arteries: 4-12 mL
Aortic arch injection (4-vessel): 20-50 mL
Not to exceed 150 mL cumulative dose
Peripheral Arteriography
300 mg/mL, intra-arterial single injection dose
Subclavian or femoral artery: 5-40 mL
Aortic bifurcation: 25-50 mL
Not to exceed 250 mL cumulative dose
Coronary Arteriography & Left Ventriculography
370 mg/mL, intra-arterial single injection dose
Right or left coronary artery: 3-14 mL
Left ventricle: 30-60 mL
Not to exceed 225 mL cumulative dose
Visceral Angiography
370 mg/mL, intra-arterial
Use volume and infusion rate proportional to blood flow and related to the vascular and pathological characteristics of the specific vessels being studied
Not to exceed 225 mL cumulative dose
Peripheral Venography
240 mg/mL, IV
Inject minimum volume necessary to visualize structures under examination
Not to exceed 250 mL cumulative dose
Excretory Urography
300 mg/mL, IV
~300 mg/kg, IV (with normal renal function)
Not to exceed 100 mL cumulative dose
Contrast Computed Tomography
300 mg/mL, IV
Head: 50-200 mL
Body (bolus injection): 50-200 mL
Body (rapid infusion): 100-200 mL
Not to exceed 200 mL cumulative dose
370 mg/mL, IV
Head: 41-162 mL
Body (bolus injection): 41-162 mL
Body (rapid infusion): 81-162 mL
Not to exceed 162 mL cumulative dose
Child Dose
Renal Dose
Administration
Hydrate patient adequately before and following administration
Warm contrast solution to body temperature shortly before administration to improve tolerability
Do not exceed cumulative iodine dose of 86 grams
Carefully individualize volume and concentration
Dosage volume and administration rate vary depending on injection site; see prescribing information for specific details
Contra Indications
Not for intrathecal use.
Precautions
Ensure adequate hydration. Increased risk of immune reaction with previous contrast sensitivity, allergy to iodine, asthma, hay fever and food allergies. Renal impairment, combined renal and hepatic disease, combined renal and cardiac disease, DM, sickle-cell disease, severe thyrotoxicosis, myelomatosis or anuria. Pregnancy and lactation.
Pregnancy-Lactation
Interactions
Increased risk of delayed hypersensitivity with interleukins. May cause renal impairment and induce lactic acidosis with metformin.
Adverse Effects
Side effects of Iopromide :
Vasodilatation, chest pain, hypertension, headache, pain, dizziness, nausea, vomiting, abnormal taste, urinary urgency, inj site reactions, back pain, abnormal vision.
Potentially Fatal: Anaphylaxis and thrombosis.
Mechanism of Action
Iopromide is a nonionic iodinated radiographic contrast medium. It allows visualisation of internal body structures by opacifying the path of its flow.
Note
Ultravist 370 (370 mg) Infusion manufactured by Zydus Pharmaceuticals. Its generic name is Iopromide. Ultravist 370 is availble in Nepal.
Farmaco Nepal drug index information on Ultravist 370 Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.